1. Home
  2. PHAT vs LXFR Comparison

PHAT vs LXFR Comparison

Compare PHAT & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • LXFR
  • Stock Information
  • Founded
  • PHAT 2018
  • LXFR 1898
  • Country
  • PHAT United States
  • LXFR United States
  • Employees
  • PHAT N/A
  • LXFR N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • LXFR Major Chemicals
  • Sector
  • PHAT Health Care
  • LXFR Industrials
  • Exchange
  • PHAT Nasdaq
  • LXFR Nasdaq
  • Market Cap
  • PHAT 339.8M
  • LXFR 274.4M
  • IPO Year
  • PHAT 2019
  • LXFR 2012
  • Fundamental
  • Price
  • PHAT $3.96
  • LXFR $9.84
  • Analyst Decision
  • PHAT Strong Buy
  • LXFR
  • Analyst Count
  • PHAT 5
  • LXFR 0
  • Target Price
  • PHAT $22.50
  • LXFR N/A
  • AVG Volume (30 Days)
  • PHAT 1.2M
  • LXFR 128.2K
  • Earning Date
  • PHAT 05-08-2025
  • LXFR 04-29-2025
  • Dividend Yield
  • PHAT N/A
  • LXFR 5.26%
  • EPS Growth
  • PHAT N/A
  • LXFR N/A
  • EPS
  • PHAT N/A
  • LXFR 0.68
  • Revenue
  • PHAT $55,252,000.00
  • LXFR $391,900,000.00
  • Revenue This Year
  • PHAT $202.23
  • LXFR $2.26
  • Revenue Next Year
  • PHAT $113.81
  • LXFR $5.85
  • P/E Ratio
  • PHAT N/A
  • LXFR $14.45
  • Revenue Growth
  • PHAT 8001.47
  • LXFR N/A
  • 52 Week Low
  • PHAT $3.81
  • LXFR $9.38
  • 52 Week High
  • PHAT $19.71
  • LXFR $15.64
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 37.83
  • LXFR 34.96
  • Support Level
  • PHAT $3.87
  • LXFR $9.41
  • Resistance Level
  • PHAT $5.09
  • LXFR $10.80
  • Average True Range (ATR)
  • PHAT 0.59
  • LXFR 0.59
  • MACD
  • PHAT -0.10
  • LXFR -0.01
  • Stochastic Oscillator
  • PHAT 6.12
  • LXFR 18.22

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

Share on Social Networks: